YOUR empty PET bottles have somewhere better to go than landfills, and SM is taking them there. Through the newly deployed Green Recycling Machines (GR Machines), SM Prime Holdings Inc. (SM Prime) uses the nationwide reach of SM Supermalls to make sustainable action easy, accessible and rewarding for mallgoers all over the country.“The GR Machines enrich the SM Group’s existing waste management efforts under the SM Green Movement,” said SM Supermalls President Steven Tan. “Through the deployment of these ma ...

Core Viewpoint - OSL Group has launched USDGO, a regulated U.S. dollar stablecoin aimed at enhancing cross-border payments and liquidity management for enterprises in Asia and globally [2][6]. Group 1: Product Overview - USDGO is a federally regulated stablecoin that is 1:1 backed by U.S. dollars and undergoes stringent third-party audits, ensuring compliance and security [3][9]. - An initial batch of USDGO stablecoins amounting to US$50 million has been minted and deployed on the Solana blockchain, with plans for future expansion to additional chains [3][4]. - The stablecoin is designed to provide 24/7 liquidity support for various users, including corporations, institutions, and individuals, facilitating a low-friction trading and settlement experience [4][5]. Group 2: Target Market and Applications - USDGO aims to address compliance and technical assurance for enterprise clients, offering capabilities for cross-chain, cross-platform, and cross-currency transactions [5][6]. - The stablecoin is positioned to serve high-frequency business scenarios such as cross-border e-commerce, international trade, and financial services, enhancing efficiency over traditional payment channels [5][9]. - OSL Group envisions USDGO as a primary choice for global enterprises seeking compliant on-chain payment solutions, thereby empowering the real economy [6][9]. Group 3: Strategic Partnerships - Anchorage Digital Bank, the issuer of USDGO, is the first federally chartered crypto bank in the U.S., collaborating with OSL Group to ensure the stablecoin's integration into existing financial systems [3][7]. - The partnership aims to advance the adoption of compliant digital assets within real payment flows and treasury environments, reflecting a significant step forward for the industry [7][9].

Core Insights - FTI Consulting is expanding its Strategy & Transformation practice in the Middle East by appointing healthcare experts Oussama Nicolas and Tara Makarem as Senior Managing Directors [1][2] Group 1: Company Expansion - The new healthcare and life sciences offering will support clients in the UAE, Saudi Arabia, and Qatar across both public and private sectors [1] - The appointments aim to strengthen FTI Consulting's capabilities in healthcare transformation and modernization of healthcare systems [2] Group 2: Leadership Expertise - Oussama Nicolas has over 25 years of healthcare consulting experience, focusing on strategy, transformation, and large-scale execution [2][3] - Tara Makarem brings more than 12 years of experience in healthcare consulting, specializing in strategy design and transformation management [3][4] Group 3: Strategic Focus - The focus of the new offering is on designing and implementing sustainable healthcare strategies that provide lasting value [3] - FTI Consulting aims to enhance its execution capabilities to achieve better long-term outcomes for patients and communities [4] Group 4: Company Overview - FTI Consulting has over 8,100 employees in 32 countries and generated $3.70 billion in revenues during fiscal year 2024 [4]

HONG KONG, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SQRIL (pronounced squirrel), the Southeast Asia based startup that provides a payments API switch for banks, ewallets and crypto apps to scan & pay local QR codes across emerging markets, announced from the sidelines of the Consensus conference in Hong Kong that it would now support several countries in Latin America. SQRIL Founder & CEO Malcolm Weed explains that, “any bank, ewallet or crypto app that integrates with our APIs would allow their user base to scan ...

Group 1 - SoftBank Group Corp's shares increased over 10% following its telecom arm, SoftBank Corp, raising its full-year profit outlook and positive sentiment around Arm Holdings' AI exposure [1] - For the first nine months of fiscal 2025, SoftBank Corp reported an 8% revenue increase to 5.2 trillion yen and an 8% rise in operating income to 884 billion yen, marking a record for the period [1] - The telecom subsidiary revised its full-year revenue forecast to 6.95 trillion yen from 6.7 trillion yen and increased its operating income target to 1.02 trillion yen, indicating steady execution towards fiscal 2025 goals [2] Group 2 - The consumer business saw a modest revenue gain of 3%, with segment income rising by 6%, despite a loss of 100,000 smartphone subscribers in the third quarter due to a tightened customer-acquisition policy [3]

Core Viewpoint - Medpace Holdings, Inc. (MEDP) is rated a Buy based on the analysis conducted on April 4, 2025, indicating a positive outlook for the stock [1]. Company Analysis - The analyst has a beneficial long position in MEDP shares, indicating confidence in the company's future performance [1]. - The focus of the analysis is on identifying strong businesses at reasonable prices, suggesting that Medpace is perceived as a solid investment opportunity [1]. Investment Strategy - The investment approach includes a mix of long-term holding and trend-following strategies, reflecting a comprehensive investment philosophy [1]. - There is a slight bias towards technology companies, but the analysis maintains a broad perspective, including opportunities in other sectors such as crypto [1].

Global Times: Feng Jicai: My thoughts on the 'Bingwu' Year of the Horse [Accessibility Statement] Skip NavigationBEIJING, Feb. 9, 2026 /PRNewswire/ -- I was born under the Chinese zodiac sign of the Horse, a sign that revisits me every 12 years in a cycle as constant as the seasons. The year 2026 is the seventh Year of the Horse that I have welcomed. Already, I hear the distinct and resonant sound of its hooves galloping closer from the far horizon.My lifelong friend Han Meilin, a renowned Chinese artist, e ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Adjustment of F&O Contracts for NMDC - The strikes of NMDC options and the base price of futures contracts will be revised due to extraordinary dividends effective February 13, 2026 [1] - All positions in futures contracts will be marked-to-market on the last cum-dividend date, February 12, 2026, based on the daily settlement price [2] - Open positions will be carried forward at the daily settlement price less ₹2.50, which is the dividend amount [2] - Daily mark-to-market settlement of futures contracts will continue as per normal procedures from February 13, 2026 [3] Example of Futures Contracts Adjustment - If 1 lot (6750 quantities) of NMDC February futures is bought at ₹85 on February 12, 2026, and the daily settlement price is ₹87, a mark-to-market profit of ₹2 per share is realized [4] - On February 13, 2026, the position will be carried forward at ₹84.50, and if the closing price is ₹86, a mark-to-market profit of ₹1.50 per share will be achieved [4] Adjustment for Option Contracts - The full value of the dividend, ₹2.50, will be deducted from all cum-dividend strike prices on the ex-dividend date [5] - Existing positions in strike prices will continue to exist in the corresponding new adjusted strike prices [5] - For instance, the strike price of the ₹85 Call Option will be reduced to ₹82.50 on February 13, 2026, while the lot size of the F&O contracts will remain unchanged [6] - Equity shareholders of NMDC as of February 13, 2026, will be entitled to receive the dividend, credited to their primary bank account within 30 to 45 days from the record date [6]

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. for the period between October 10, 2023, and December 26, 2025, indicating potential legal challenges for the company [1]. Company Overview - Inovio Pharmaceuticals, Inc. is described as a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating and protecting individuals from diseases, including those associated with human papillomavirus (HPV) [1].